NCT02751528 2025-01-13
QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
NantBioScience, Inc.
Phase 1 Terminated
NantBioScience, Inc.
Andes Biotechnologies
Spectrum Pharmaceuticals, Inc